

# CURRICULUM VITAE

*LILI G. KAPLAN, MD*

## OFFICE ADDRESSES

Retina Associates of Cleveland, Inc.  
3401 Enterprise Parkway, Suite 300; Cleveland, Ohio 44122  
14725 Detroit Avenue, Suite 200; Cleveland, Ohio 44107  
15299 East Bagley Road, Suite 200; Cleveland, Ohio 44130  
17534 Royalton Road, Suite 201; Cleveland, Ohio 44136  
5390 Belmont Avenue; Youngstown, Ohio 44505  
690 White Pond Drive, Suite 120; Akron, Ohio 44320  
170 North Road NE; Warren, Ohio 44483  
9485 Mentor Avenue, Suite 211; Mentor, Ohio 44060  
6100 South Broadway Avenue, Suite 200; Lorain, Ohio 44052

## TELEPHONE

216-831-5700

## WEBSITE

[www.retina-doctors.com](http://www.retina-doctors.com)

## EDUCATION

### *College*

University of Pennsylvania College of Arts and Sciences  
Philadelphia, Pennsylvania  
1997–2001, BA (magna cum laude; Major, Biological Basis of  
Behavior; Minor, Psychology)

### *Medical School*

University of Pennsylvania School of Medicine  
Philadelphia, Pennsylvania  
2002–2006, MD

## POSTGRADUATE TRAINING

### *Internship*

Internal Medicine and General Surgery  
University of Pennsylvania  
Philadelphia, Pennsylvania  
2006–2007

### *Residency*

Ophthalmology Residency  
University of Pennsylvania Scheie Eye Institute  
Philadelphia, Pennsylvania  
2007–2010

### *Fellowship*

Medical Retina Fellowship  
Duke University Eye Center  
Durham, North Carolina  
2010–2011

## LICENSURE AND BOARD CERTIFICATION

Licensed to practice medicine in Ohio and Pennsylvania

Diplomate, American Board of Ophthalmology, 2011

## PROFESSIONAL POSITIONS

Retina Associates of Cleveland, 2014–

Private practice in vitreoretinal surgery and diseases. Associates: Lawrence J. Singerman, MD; Michael A. Novak, MD; Hernando Zegarra, MD; Z. Nicholas Zakov, MD; Scott D. Pendergast, MD; David G. Miller, MD; Joseph M. Coney, MD; Jerome P. Schartman, MD; Llewelyn J. Rao, MD; Shawn A. Lewis, MD

Lancaster Retina Specialists, Lancaster, Pennsylvania; 2012–2014

Kay, Tabas & Niknam Ophthalmology Associates, Wills Eye Institute, Jefferson University, Philadelphia, Pennsylvania; 2011–2014

Pennsylvania Academy of Ophthalmology Advocacy Ambassador

## HONORS AND AWARDS

National Eye Institute Association for Research in Vision and Ophthalmology research award

American Society of Cataract and Refractive Surgery Resident Excellence Award

Max Kade Fellowship, University of Pennsylvania School of Medicine

Benjamin Franklin Scholar Undergraduate Honors Student, University of Pennsylvania College of Arts and Sciences

## MEMBERSHIPS

American Academy of Ophthalmology  
American Board of Ophthalmology  
Cleveland Ophthalmological Society  
American Society of Retinal Specialists

## RESEARCH ACTIVITIES

### *National Clinical Trials*

*Phase II, multicenter, randomized, single-masked, sham-controlled study of safety, tolerability and evidence of activity of intravitreal APL-2 therapy in patients with geographic atrophy (GA)*

Co-investigator, 2015–

*Phase III double masked study of safety and efficacy of abicipar pegol in patients with neovascular age-related macular degeneration*

Co-investigator, 2015–

*Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration*

Co-investigator, 2015–

*An 18-month Phase 2a open label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer)*

Co-investigator, 2015–

*LHA510 proof-of-concept study as a maintenance therapy for patients with wet age-related macular degeneration*

Co-investigator, 2015–

*Randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH-258 versus aflibercept in subjects with neovascular age-related macular degeneration*

Co-investigator, 2015–

*Phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration (PROXIMA)*

Co-investigator, 2015–

*A study investigating the efficacy and safety of lampalizumab intravitreal injections in patients with geographic atrophy secondary to age-related macular degeneration (CHROMA)*

Co-investigator, 2015–

*A study of lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy (EXPOSURE)*

Co-investigator, 2015–

*Natural history and registry study of macular telangiectasia (MacTel)*

Co-investigator, 2015–

*Ocriplasmin Research to Better Inform Treatment (ORBIT)*

Co-investigator, 2015–2016

***Other Research Activities***

*Spectral domain optical coherence tomography (SD-OCT) in age-related macular degeneration: automated segmentation of drusen in SD-OCT in the Age-Related Eye Disease Study (AREDS) 2*

Duke University Eye Center, 2010–2011

*Indocyanine green (ICG) angiography in age-related macular degeneration: ICG subtypes of choroidal neovascularization*

Duke University Eye Center, 2010–2011

*Uveitis epidemiology research: evaluation of the risk of relapse of a first episode of uveitis*

University of Pennsylvania, Scheie Eye Institute, 2009–2010

- Presented results at the American Uveitis Society, American Academy of Ophthalmology, and Scheie Eye Institute Alumni Day meetings
- Paper published in *Ophthalmology*, 2011

*Retinal vessel dilation in retinopathy of prematurity: analysis of retinal vessel diameters in fundus photographs*

University of Pennsylvania, Scheie Eye Institute, 2007–2010

- Designed study
- Presented results at Scheie Eye Institute Alumni Day Conference
- Paper published in *Am J Ophthalmol*, 2009

**SELECTED PRESENTATIONS AT MEETINGS AND SYMPOSIA**

1. Plaquenil retinopathy progression after cessation of the drug. Optometric Retinal Update Seminar. Beachwood, Ohio, February 18, 2016.
2. Plaquenil retinopathy progression after cessation of the drug. Cleveland Ophthalmological Society Meeting. Cleveland, Ohio, February 9, 2016.
3. Interesting retinal cases. Optometric Retinal Update Seminar. Akron, Ohio, November 4, 2015.
4. Interesting retinal cases. Optometric Retinal Update Seminar. Cleveland, Ohio, March 12, 2015.
5. Diabetic retinopathy case studies. Cleveland Ophthalmological Society Meeting. Cleveland, Ohio, October 14, 2014.
6. Grunwald L, Newcomb CW, Daniel E, et al. Risk of relapse in primary acute anterior uveitis. American Uveitis Society Spring Meeting. Fort Lauderdale, Florida, May 2011.

7. Grunwald L, Newcomb CW, Daniel E, et al. Risk of relapse for patients with primary anterior uveitis. American Academy of Ophthalmology Annual Meeting. Chicago, Illinois. October 2010. E-Abstract PA038.
8. Grunwald L, Newcomb CW, Daniel E, et al. Risk of relapse for patients with primary anterior uveitis. Scheie Eye Institute 136<sup>th</sup> Alumni Day Conference. Philadelphia, Pennsylvania, 2010.
9. Grunwald L, Mills MD, Johnson KS, Karp KA, Quinn GE, Ying GS, Grunwald JE. Rate of retinal vessel dilation in severe retinopathy of prematurity. Scheie Eye Institute 135<sup>th</sup> Alumni Day Conference. Philadelphia, Pennsylvania, 2009.
10. Grunwald L, Niknam RL, Ying GS, Sankar P, Nduaguba C, Miller E. Effect of corneal thickness on intraocular pressure reduction. Scheie Eye Institute 133<sup>rd</sup> Alumni Day Conference 2007, Philadelphia, Pennsylvania, 2007.
11. Grunwald JE, Metelitsina T, Grunwald L. Effect of sildenafil citrate (Viagra) on retinal blood vessel diameter. International Symposium on Ocular Pharmacology and Pharmaceutics (ISOPP). Seville, Spain, February 28–March 3, 2002.

## PUBLICATIONS

### *Book Chapters*

1. Brod R, Grunwald L. Endophthalmitis. In Schlossberg D (ed.): *Clinical Infectious Disease*, 2nd Edition. Cambridge, UK: Cambridge University Press. In press.
2. Grunwald L, Chen L, Bunya V. Paget's Disease. In Maguire J, Murchison A, Jaeger E: *5-Minute Consult*. Philadelphia, PA: Lippincott Williams and Wilkins, 2012. pp. 508-509.

### *Articles*

1. Berenberg TL, Metelitsina TI, Madow B, Dai Y, Ying GS, DuPont JC, Grunwald L, Brucker AJ, Grunwald JE. The association between drusen extent and foveolar choroidal blood flow in age-related macular degeneration. *Retina* 2012;32:25-31.
2. Grunwald L, Newcomb CW, Daniel E, Kaçmaz RO, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Kempen JH. Risk of relapse in primary acute anterior uveitis. *Ophthalmology* 2011;118:1911-1915.
3. Grunwald L, Kligman B, Shields C. Acute exudative polymorphous paraneoplastic vitelliform maculopathy in a patient with carcinoma, not melanoma. *Arch Ophthalmol* 2011;129:1104-1106.
4. Grunwald L, Mehta S, Hogarty MD, Liu GT. Chronic myelogenous leukemia and retinopathy treated with Imatinib. *Retinal Cases and Brief Reports* 2011; 5:366-368.

5. Grunwald L, Mills MD, Johnson KS, Karp KA, Quinn GE, Ying GS, Grunwald JE. The rate of retinal vessel dilation in severe retinopathy of prematurity requiring treatment. *Am J Ophthalmol* 2009;147:1086–1091.
6. Barry GP, Mucha-Le Ny B, Zackai EH, Grunwald L, Forbes BJ. A case report of a patient with Pfeiffer syndrome, FGRF 2 mutation (Trp290Cys) and unique ocular anterior segment findings. *Ophthalmic Genetics*. 2010; 31:193-195.
7. Grunwald L, Sund NJ, Volpe NJ. Pupillary sparing and aberrant regeneration in chronic third nerve palsy secondary to posterior communicating artery aneurysm. *Br J Ophthalmol* 2008; 92):715-716.
8. Grunwald JE, Metelitsina T, Grunwald L. Effect of sildenafil citrate (Viagra) on retinal blood vessel diameter. *Am J Ophthalmol* 2002; 133:809-812.

### **Posters**

1. Grunwald Kaplan L, Zegarra H. Long-term progression of hydroxychloroquine retinopathy: seventeen cases followed for 26-130 months after drug cessation. Poster #PO245. American Academy of Ophthalmology Annual Meeting. Chicago, Illinois, October 16, 2016.
2. Mettu PS, Crowell S, Shaw J, Grunwald L, Lad EM, Serrano N, Cousins SW. Neovascular morphology on ICG angiography predicts response to anti-VEGF therapy in eyes with serous pigment epithelial detachments and age-related macular degeneration. Program#/Poster#2654/D1096. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Fort Lauderdale, Florida, May 2012.
3. Lad EM, Grunwald L, Mettu PS, Serrano NP, Crowel S, Cousins SW. Lesion morphology on indocyanine green angiography in age-related macular degeneration with classic choroidal neovascular membrane: implications for response to anti-VEGF treatment. Program#/Poster# 5161/D1214. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Fort Lauderdale, Florida, May 2012.
4. Grunwald L, Schuman S, Leuschen JN, et al. Comparison of Spectral Domain Optical Coherence Tomography characteristics of intermediate versus advanced Age Related Macular Degeneration in AREDS2. Program#/Poster# 159/A41. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Fort Lauderdale, Florida, May 2011.
5. Grunwald L, Ying GS, Quinn GE, Dai Y, Karp KA, Fiorin D, Ruggeri A, Grunwald JE, Mills MD. Retinal vessel tortuosity in infants at risk for retinopathy of prematurity between 31 and 34 weeks post-menstrual age. Program#/Poster# 5919/A114. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Fort Lauderdale, Florida, May 2010.

6. Grunwald L, Mills MD, Ying GS, Grunwald JE, Karp KA, Dai Y, Fiorin D, Ruggeri A, Quinn GE. Retinal vessel width in infants at risk for retinopathy of prematurity between 31 and 34 weeks post-menstrual age.#3134. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Fort Lauderdale, Florida, May 2009.
7. Grunwald L, Mills MD, Johnson KS, Karp KA, Ying GS, Grunwald JE. Does change in retinal vessel diameter over time predict severe retinopathy of prematurity? #1383. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Fort Lauderdale, Florida, May 2008.
  - Received National Eye Institute (NEI) Award
8. Grunwald L, Niknam RL, Ying GS, Sankar P, Nduaguba C, Miller E. Effect of corneal thickness on intraocular pressure reduction. #1279. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Fort Lauderdale, Florida, May 2007.